Company Overview

Update
Status:
Acquired by Cubist Pharmaceuticals
Founders:
Dennis Podlesak
Headquarters:
San Mateo, CA
Categories:
Biotechnology
Description:
Calixa Therapeutics, a biopharmaceutical company, develops a novel cephalosporin to address the problem of multi-drug resistant organisms.

Detailed Description

Update

Calixa Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of a novel cephalosporin to address the expanding problem of multi-drug resistant organisms. Treatment of infections caused by resistant gram-negative bacteria, especially Pseudomonas aeruginosa, is recognized as an unmet medical need by the infectious diseases community.

Calixa’s lead product, CXA-101, is an IV formulation of a novel cephalosporin that has excellent potency especially against multi-drug resistant Pseudomonas aeruginosa, which differentiates it from other cephalosporins. No similar drug is known to be in development. Calixa plans to combine this product with a β-lactamase inhibitor; the combination product (CXA-201) has the potential to become the first-line therapeutic choice for hospitalized patients suffering from serious infection caused by gram-negative organisms.

Current Team (2)

Update

Past Team (2)

Update

Offices/Locations (1)

Update
  • Office

    1840 Gateway Drive

    Suite 200

    San Mateo, CA 94404

    USA

Images (1)

Update
  • 1c1a8b858252f654e02281a1e74c701c